High Sensitivity and NPV for BinaxNOW Rapid Antigen Test in Children at a Mass Testing Site during Prevalent Delta Variant Period

Abstract

The BinaxNOW rapid antigen COVID-19 test had a sensitivity of nearly 92% in both symptomatic and asymptomatic children when performed at a high-throughput setting during the more transmissible delta variant dominant period. The test may play an invaluable role in asymptomatic screening and keeping children safe in school.

Nasal swab is a good alternative sample for detecting SARS-CoV-2 with rapid antigen test: A meta-analysis

“…Among the 49 studies on nasal swabs containing 79,073 samples [ [2] , [3] , [4] , 6 , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] ], all of them were published between 2021 and 2022, and twenty-one studies were conducted in the USA [ 12 , 14 , 15 , 18 , 21 , 22 , [25] , [26] , [27] , [32] , [33] , [34] , [35] , 39 , 44 , 45 , [47] ...…”

Update of European Society of Clinical Microbiology and Infectious Diseases coronavirus disease 2019 guidelines: diagnostic testing for severe acute respiratory syndrome coronavirus 2

“… In patients with signs and symptoms compatible with COVID-19, we suggest the use of rapid antigen detection testing in respiratory samples other than nasopharyngeal and saliva samples versus laboratory-based NAAT in samples other than nasopharyngeal and saliva samples for the diagnosis of COVID-19. Weak for Low [ 9 , 26 , [114] , [115] , [116] , [117] , [118] , [119] , [120] , [121] , [122] , [123] , 93 , [124] , [125] , [126] , [127] , [128] , [107] , [108] , [109] , [110] , [111] , [112] , [113] ] 15 In patients with signs and symptoms compatible with COVID-19 of equal or less than 7 days-onset , should rapid antigen detection testing be used, compared with standard NAAT (commercial and/or in house) for diagnosis of COVID-19? In patients with signs and symptoms compatible with COVID-19 of equal or less than 7 days-onset, we suggest the use of rapid antigen detection testing versus laboratory-based NAAT for the diagnosis of COVID-19.…”

“… In patients ≥ 12 years old with signs and symptoms compatible with COVID-19, we suggest the use of laboratory-based NAAT versus rapid antigen detection testing for the diagnosis of COVID-19. Weak against Low [ 4 , 6 , 25 , 28 , 33 , 34 , 37 , [41] , [42] , [43] , [44] , 46 , 7 , 48 , 49 , [53] , [54] , [55] , [62] , [63] , [64] , 70 , 71 , 10 , 77 , 82 , 83 , 90 , 94 , 108 , 109 , 111 , 113 , 115 , 11 , 116 , 119 , 123 , 128 , 130 , 133 , [135] , [136] , [137] , 140 , 17 , [143] , [144] , [145] , [146] , [147] , [148] , [149] , [150] , [151] , ...…”

“… In asymptomatic patients ≥12 years old without risk factors for severe COVID-19, we suggest the use of laboratory-based NAAT versus rapid antigen testing for the diagnosis of COVID-19. Weak against Low [ 11 , 20 , 49 , 54 , 55 , 65 , 70 , 71 , 77 , 83 , 89 , 94 , 22 , 111 , 113 , 121 , 128 , 130 , 137 , [143] , [144] , [145] , [146] , 24 , [147] , [148] , [149] , 158 , [160] , [161] , [162] , [163] , [164] , [165] , 28 , [166] , [167] , [168] , [169] , [170] , [171] , [172] , [173] , [174] , [175] , 34 , 176 , 40 , 43 , 44 , 46 ] 3 In asymptomatic people of any age with any risk factor(s) for severe COVID-19 (including age <3 or ≥65 years) should rapid antigen tests be used, as compared to laboratory-based ...…”

“… In asymptomatic people, we suggest the use of laboratory-based NAAT in non-nasopharyngeal/non-saliva respiratory samples versus rapid antigen testing in non-nasopharyngeal/non-saliva for the diagnosis of COVID-19. Weak against Low [ 107 , 110 , 128 , 154 , 156 , 159 , 164 , 167 , 171 , 111 , 112 , 118 , [120] , [121] , [122] , 124 , 126 ] 6 In asymptomatic people should rapid antigen tests be used in saliva samples as compared laboratory based NAAT to diagnose COVID-19? In asymptomatic people, we suggest the use of laboratory-based NAAT in saliva samples versus rapid antigen testing in saliva for the diagnosis of COVID-19.…”